Altimmune (ALT) Accumulated Depreciation & Amortization (2010 - 2025)

Altimmune (ALT) has 16 years of Accumulated Depreciation & Amortization data on file, last reported at $2.3 million in Q4 2025.

• Quarterly Accumulated Depreciation & Amortization rose 5.06% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (up 5.06% YoY) and the FY2025 annual result came in at $2.3 million, up 5.06% from the prior year.
• Accumulated Depreciation & Amortization grew to $2.3 million in Q4 2025 per ALT's latest filing, from $2.2 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $2.3 million in Q4 2025 and bottomed at $1.1 million in Q1 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $1.9 million (2021), against an average of $1.9 million.
• The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization plunged 36.08%; it then jumped 31.84% in 2023.
• Tracing ALT's Accumulated Depreciation & Amortization over 5 years: stood at $2.0 million in 2021, then fell by 26.82% to $1.5 million in 2022, then soared by 31.84% to $2.0 million in 2023, then increased by 12.05% to $2.2 million in 2024, then advanced by 5.06% to $2.3 million in 2025.
• Per Business Quant, the three latest ALT Accumulated Depreciation & Amortization figures stand at $2.3 million (Q4 2025), $2.2 million (Q4 2024), and $2.0 million (Q4 2023).

Peer Comparison